eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2011
vol. 7
 
Share:
Share:
more
 
 

Clinical research
Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer

Zbigniew Jabłonowski
,
Edyta Reszka
,
Jolanta Gromadzińska
,
Wojciech Wąsowicz
,
Marek Sosnowski

Arch Med Sci 2011; 7, 3: 512-516
Online publish date: 2011/07/11
Article file
- Hypermethylation.pdf  [0.07 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

During the last two decades, research concerning the aetiology of cancer disease has been considering not only causes such as carcinogen or mutagen damage of DNA, but also the processes of non-genotoxic cancer aetiology. It is suggested that epigenetic changes which concern inherited changes of gene expression are not connected with changes in the genome sequence.

Epigenetic control of gene transcription includes methylation of the DNA and covalent modifications, such as acetylation and methylation, of chromatin’s histone proteins [1, 2]. Both mechanisms are closely linked to each other. Hypomethylation of the genomic DNA, which is connected to the activation of the oncogene, as well as hypermethylation of the promoter regions or exons of tumour suppressor genes, are observed in neoplastic cells.

Excessive methylation of CpG islands was found in anti-oncogene promoter regions, which were associated with the repair of damaged DNA (MLH1, 06-MGMT, BRCA1), metastases and invasiveness of the cancer genesis process (E-cadherin, VHL, APC) metabolism of xenobiotics (GSTP1), apoptosis (DAPK), cell cycle (Rb, p16, p15, p14, p73) and other cell processes (ER, RAR-) of patients with varied tumour locations [3].

It is suggested that changes in the degree of methylation of DNA in cancer disease may determine the process of cancer genesis, mainly due to ‘silencing’ of the transcription process.

The product of the DAPK gene is considered to be a positive mediator of apoptosis, and moreover it is connected with the suppression of neoplastic processes [4, 5]. The p16INK4a protein belongs to a family of regulators of the cell cycle, called cyclin-dependent kinase inhibitors (CDKI), which bind themselves to cyclin-CDK complexes. The formation of such complexes causes, as a result, the arrest of the cell cycle in the G1 phase. This is also the way through which the p16INK4a protein can stop the proliferation of neoplastic cells [6].

The aim was to examine the frequency of hypermethylation in promoter regions of p16 and DAPK genes in patients with non-invasive bladder cancer.

Material and methods

Forty-two patients, citizens of central Poland, with non-invasive urinary bladder cancer, of different grading (G) were examined. Methylation of promoter regions of the p16 anti-oncogene, a gene involved in the regulation of the cell cycle, and the DAPK gene (death-associated protein kinase), which is involved in processes of programmed cell death, was analysed. The histopathological classification of urinary bladder cancer was confirmed by two independent histopathologists.

The reference group, chosen on the basis of age and gender, consisted of 36 healthy control volunteers. Before blood samples were taken, participants of the study were interviewed with a questionnaire. The questionnaire included questions concerning demographic data, place of residence, history of cigarette addiction and of employment.

The majority of patients in the control group (91.7%) and the study group (92.9%) were men. In the group with urinary bladder cancer 73.8% people smoked cigarettes and in the reference group the smokers constituted 69.4% of the group. In the group of patients with non-invasive urinary bladder cancer, most cases (71.4%) were characterized by a low degree of neoplasm and clinical progression (T1G1). The characteristics of both groups as well as data concerning the clinical progression and the degree of neoplasm in patients with urinary bladder cancer are presented in Table I.

Permission to conduct the research was granted by the Local Ethics Commission of Scientific Research (Resolution no. 25/2003 dated 2.06.2003). After being acquainted with the aim and the methods used in the study, as well as the possibility to quit the study at any desired moment, each of the patients included in the study or reference group signed a written informed consent form.

Before any treatment, peripheral blood samples were taken from both groups of patients.

In order to detect the methylation status of the two chosen genes, specifically the p16 and the DAPK gene, in peripheral blood, the MSP method (methylation-specific PCR) was used.

Blood samples collected from each participant were stored at –70°C before DNA isolation. DNA samples were extracted from 200 µl of blood serum using the procedures of QIAamp DNA Blood Mini Kit (Syngen Biotech, Poland). Sodium bisulfite conversion of 1 µg of genomic DNA was performed with CpGenome Modification Kit (Millipore, Biokom, Poland). After bisulfite conversion, the methylation analysis was conducted by the MSP assay. Primers for determination of methylated or unmethylated p16 and DAPK alleles have been described elsewhere [7-9]. A nested, two-stage PCR approach was used for p16 methylation status analysis described by Palmisano et al. After 1st stage PCR with primers specific to methylated or unmethylated template, 280-bp products were 50-fold diluted and 2 µl of diluted amplicons were used in the 2nd stage PCR. Primer sequences, product sizes and annealing temperatures used for MSP analysis are presented in Table II. The methylation status of the p16 was determined with AmpliTaqGold polymerase (Applied Biosystems, Poland) and of the DAPK gene with HotStarTaq polymerase (Qiagen, Syngen Biotech, Poland) in a 20 µl volume. CpGenome universal methylated DNA (Millipore, Biokom, Poland) served as a positive control of methylated alleles.

After amplification, PCR products were electrophoresed on 1% agarose with ethidium bromide along with DNA ladder and then visualized and analysed. Samples with ambiguous results were re-tested and 10% of all samples were repeated.

To analyse the material, the 2 test, Student’s t-test and non-parametric Mann-Whitney-U test were used. Statistical significance was defined as a value p < 0.05.

Results

Analysis of the profile of methylation in patients with urinary bladder cancer shows that 17 out of 42 patients (40.5%) presented hypermethylation of the p16 gene, while methylation of the DAPK gene was seen in 27 of 42 cases (64.3%). In the case of 12 patients (28.6%) both analysed genes were methylated, and in the case of 10 patients (23.8%), promoter regions of p16 and DAPK genes were unmethylated. A statistically significant (p = 0.046) higher frequency of hypermethylation of the DAPK gene (71.4%) was observed in patients with low grade (G1) urinary bladder cancer in comparison to patients with the G2 and G3 form (55%). Such a dependency was not observed in the case of p16 gene methylation. A statistically significant difference in the frequency of hypermethylation of the p16 and DAPK genes was not seen in association with age and cigarette smoking.

Methylation of the p16 and DAPK genes was not observed in blood serum of patients from the control group. Table III presents the results of hypermethylation of promoter regions in the p16 and DAPK genes.

Discussion

It has been suggested that changes in the degree of methylation in DNA regulatory regions, observed during the course of neoplastic disease, can influence the process of cancer genesis through ‘silencing’ of the process of transcription. Some studies have found that the hypermethylation of promoter regions mainly involves genes responsible for control of the cell cycle and apoptosis, DNA damage repairing genes, and genes connected with the metabolism of xenobiotics [7].

In the presented project, the anti-oncogene p16 and DAPK were chosen to analyse the hypermethylation of promoter regions in genomic DNA isolated from blood serum of bladder cancer patients. The p16 gene is involved in the regulation of the cell cycle while the DAPK gene is committed to a process of programmed cell death. p16 and DAPK genes are closely connected with the process of cancer genesis, by inducing the suppression of cell proliferation. So far, in Poland, research concerning the promoter hypermethylation of genomic DNA from blood has not been conducted. At the same time, in world literature, the role of epigenetic regulation of the p16 and DAPK genes in urinary bladder cancer has not been completely explained.

Past researchers have used neoplastic tissues to estimate the degree of DNA hypermethylation. Many authors claim that peripheral blood, serum and plasma can be good diagnostic material for the detection of changes, such as DNA hypermethylation, in nucleic acids [8-10]. Valenzuela et al. observed a statistically significant dependence between the methylation of p16 in the promoter region in tissue and plasma, while examining 86 people with urinary bladder cancer. Dominguez et al. achieved similar results, assessing, among other things, the hypermethylation of promoter p14 and p16 regions in 27 urinary bladder cancer patients [11].

Excessive methylation of CpG islands (cytosine, phosphorylated guanine), which occurs in the promoter regions, is observed in various types of tumours. As a consequence, hypermethylation can lead to the decrease of transcription activity of specific genes and can play an important role in the induction of the cancer genesis process. Some authors claim that even up to 65% of cases of neoplastic disease may be linked to these epigenetic changes [9].

Hypermethylation of promoter regions in the p16 and DAPK genes does not occur in healthy people. This confirms our observations.

Many authors have observed hypermethylation, in 7% to 60% of cases, of the p16 gene, in patients with urinary bladder cancer [12-16]. In our study, patients with urinary bladder cancer, in whom hypermethylation of the p16 gene was seen, made up 40.5%.

In the case of DAPK, hypermethylation was found in 4% to 45.5% of patients with urinary bladder cancer [14-16], but when counting all of the patients examined in our centre, this proportion was 64.3%. The observed variation could be the result of differences in the sensitivity of our method of detection of DNA methylation as well as of the heterogeneity of the sample taken [17]. Some of the authors also paid attention to the correlation between DNA methylation and the time of progression of the neoplastic disease. Higher frequency of hypermethylation in the DAPK gene was observed in the beginning stages of neoplastic disease [18-21].

Tada et al. claimed that the assessment of the changes in DAPK methylation can be a prognostic factor of non-invasive urinary bladder cancer recurrences [22]. They proved that the percentage of recurrences of the disease was 88% among those patients in whom DAPK hypermethylation was found, while it was only 28% among those patients in whom gene methylation was not seen. We observed a higher frequency in DAPK gene hypermethylation (71.4%) among patients with urinary bladder cancer of lower malignancy (grade G1) in comparison to patients with grades G2 and G3 (55%). A longer follow-up of these patients could help us explain the above observations.

In conclusion, detection of the aberrant methylation of DAPK and p16 genes in blood DNA from non-invasive bladder cancer patients might offer an effective means for the earlier auxiliary diagnosis of the malignancy. The usefulness of the above-mentioned research, in clinical practice, still has to be evaluated.

Acknowledgments

This study was supported by a Ministry of Science and Higher Education grant (No. N N403 188434) and by an internal grant (IMP1.3/2004).

References

 1. Bombail V, Moggs JG, Orphanides G. Perturbation of epigenetic status by toxicants. Toxicol Let 2004; 149: 51-8.  

2. Moggs JG, Goodman JI, Trosko JE, Roberts RA. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol 2004; 196: 442-30.  

3. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. PNAS 1996; 93: 9821-6.  

4. Velentza AV, Schumacher AM, Weiss C, Egli M, Watterson DM. A protein kinase associted with apoptosis and tumor suppression. J Biol Chem 2001; 276: 38956-65.  

5. Yukawa K, Hoshino K, Kishino M, et al. Deletion of the kinase domain in death-associated protein kinase attenuates tubular cell apoptosis in chronic obstructive uropathy. Int J Mol Med 2004; 13: 515-20.

6. Brown I, Milner BJ, Rooney PH, Haites NE. Inactivation of the p16INK4a gene by methylation is not a frequent event in sporadic ovarian carcinoma. Oncol Rep 2001; 8: 1359-62.  

7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 2003; 349: 2042-54.  

8. Anker P, Stroun M. Tumor related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia 2001; 15: 289-91.  

9. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.

10. Wong IH. Methylation profiling of human cancers in blood: molecular monitoring and prognostication (rewiev). Int J Oncol 2001; 19: 1319-24.

11. Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002; 8: 980-5.

12. Dominguez G, Silva J, Garcia JM, et al. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res 2003; 530: 9-17.

13. Chang LL, Yeh WT, Yang SY, Wu WJ, Huang CH. Genetic alterations of P16INK4A and P14ARF genes in human bladder cancer. J Urol 2003; 170: 595-600.

14. Chan MW, Chan LW, Tang NL, et al. Hypermetylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8: 464-7.

15. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61: 8659-663.

16. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis. J Urol 2005; 173: 1767-71.

17. Poirier LA. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr 2002; 132: 2336S-9S.

18. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.

19. Esteller M, Herman JG. Cancer as an epigenic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.

20. Frühwald MC, Plass C. Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Gen Metab 2002; 75: 1-16.

21. Singal R, van Wert J, Bashambu M. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Canc Res 2001; 61: 4820-6.

22. Tada Y, Wada M, Taguchi K, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002; 62: 4048-53.
Copyright: © 2011 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe